ArticleScientific reports2026
Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrin β3: structural functions, tumour microenvironment regulatory roles and targeted intervention strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First-line treatment options for patients with metastatic hormone-sensitive prostate cancer (HSPC) are divided into two groups: androgen receptor signaling inhibitor (ARSI)-based doublet therapy and triplet therapy (which includes chemotherapy in addition to doublet therapy). However, differences in therapeutic efficacy between the two groups remain unclear. The aim of the study was to perform a comparative analysis between the two groups and to identify predictors of treatment response. We retrospectively recruited 500 patients with mHSPC treated with doublet or triplet therapy from our hospital and affiliated hospitals between 2013 and 2025. The cohort of patients with mHSPC treated with doublet therapy received ABI, ENZ, or APA in combination with a luteinizing hormone-releasing hormone analog, such as androgen deprivation therapy (ADT). The cohort of those treated with triplet therapy received darolutamide plus ADT and docetaxel. Cox proportional hazards regression analysis was performed to identify prognostic factors of overall survival in patients with mHSPC. Propensity score matching was used to adjust the clinical background of patients. The outcome (prostate-specific antigen-progression-free survival, second progression-free survival, and overall survival (OS)) of triplet therapy was significantly better than that of doublet therapy in matched high-risk patients with mHSPC. Univariate and multivariate analyses of OS in matched patients with high-risk mHSPC treated with triplet or doublet therapy suggested that treatment choice (triplet or doublet), pretreatment LDH levels, and presence of Gleason pattern 5 influenced OS in patients with high-risk mHSPC. Subgroup analysis suggested that LDH levels and the presence of Gleason pattern 5 may be predictive factors of the treatment of patients with mHSPC. Our results showed that triplet therapy achieved a better outcome than doublet therapy in patients with mHSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.